drugset / Trial / NCT00864097

Analgesic Efficacy And Safety of Tanezumab Added On To Diclofenac SR In Patients With Osteoarthritis Of The Knee Or Hip

NCT00864097

Phase 3 Terminated 607 enrolled Pfizer
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to investigate the analgesic efficacy and safety of tanezumab added on to diclofenac SR in patients with osteoarthritis of the knee or hip currently experiencing partial benefit from, and are tolerating, diclofenac 150 mg/day therapy.

Timeline

Start
2009-08-11
Primary completion
2010-11-16
Completion
2010-11-24

Drugs

EvaluationDrugModalityDoseRoute
Subject Tanezumab Monoclonal antibody 2.5 mg Intravenous
Subject Tanezumab Monoclonal antibody 5 mg Intravenous
Subject Tanezumab Monoclonal antibody 10 mg Intravenous
Comparator Diclofenac Other / unclassified 75 mg Oral

Indications